目的：探讨术前、术中化疗对胃癌5年生存率影响及术前化疗的恰当时限。方法：作者自1987年一1992年将收治的胃癌病例随机分成A、B、C、D4组（仅对能切除的病例进行研究），A组术前给3周期FM方案化疗，术中静脉给5－Fu750mg，癌床局部注射5-Fu，术后给4周期FM或FMA方案化疗;B组术前给2周期FM方案化疗，其余同A组；C组术前1周期FM方案化疗，其余同A组；D组仅术后给4周期FM或FMA方案化疗。结果：A组病例的5年生存率45．O％，B组48．4op，C组42．1％，D组32．l％。A、B、C3组合并5年生存率45．3％，与D组相比P＜0．05，而B组与D组相比P＜O.05。结论：术前、术中化疗能提高胃癌的5年生存率。而术前化疗应以2周期为宜。 Objective: To investigate the effect of preoperative and intraoperative chemotherapy on the 5-year survival rate of gastric cancer and the appropriate time limit for preoperative chemotherapy. Methods: The authors randomly divided the treated cases of gastric cancer into groups A, B, C, and D4 from 1987 to 1992 (only the resectable cases were studied). A group was given a 3-cycle FM regimen before surgery, and intraoperative veins were given. 5-Fu750mg, 5-Fu injection into the cancer bed, 4 cycles of FM or FMA after chemotherapy; B group of 2 cycles of FM chemotherapy before surgery, the rest with A group; C group of 1 cycle of FM chemotherapy before surgery, and the rest In group A, group D received only 4 cycles of FM or FMA chemotherapy. Results: The 5-year survival rate of group A cases was 45. O%, B group 48.4op, C group 42.1%, D 32. l%. The 5-year survival rate of A, B and C3 combination was 45.3%, P<0.05 compared with D group, and P